title: Prolongation of QT interval induced by electroconvulsive therapy is attenuated by landiolol.
abstract: OBJECTIVE
  The objective of this study was to determine if landiolol, ultra short-acting beta adrenoceptor antagonist, attenuates the prolongation of QT interval caused by electroconvulsive therapy (ECT).
  
  
  METHODS
  Fifteen patients, scheduled to undergo ECT for the treatment of major depression disorder, were studied. In each patient, 2 sessions of ECT were picked up and randomly assigned to be administered with (treatment L) or without continuous infusion of landiolol (treatment C). Electroconvulsive therapy was administered under general anesthesia with propofol and suxamethonium. Raw electrocardiogram waves were obtained from anesthesia monitor and stored on a personal computer. Automated electrocardiogram analyzing software was used for the determination of QT interval.
  
  
  RESULTS
  The increase in corrected QT caused by suxamethonium was significantly smaller in treatment L (36.8 +/- 14.5 ms for treatment C vs 17.9 +/- 6.5 ms for treatment L; P < 0.001). The increase in corrected QT caused by ECT was also smaller in treatment L (72.3 +/- 23.1 ms for treatment C vs 54.6 +/- 17.9 ms for treatment L; P = 0.02).
  
  
  CONCLUSIONS
  The prolongation of QT interval caused by SUX and ECT was partially attenuated by landiolol.
authors.affiliation: Department of Anesthesiology, Aichi Gakuin University School of Dentistry, Nagoya, Japan.
authors.forename: Masayo
authors.initials: M
authors.lastname: Matsura
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ito
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Kandatsu
authors.forename: Naoko
authors.initials: N
authors.lastname: Kato
authors.forename: Jun
authors.initials: J
authors.lastname: Harada
authors.forename: Toru
authors.initials: T
authors.lastname: Komatsu
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000771:Anesthesia, Intravenous; D018686:Anesthetics, Intravenous; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D003866:Depressive Disorder / Q000523:psychology / Q000628:therapy; D004565:Electroconvulsive Therapy / Q000009:adverse effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008133:Long QT Syndrome / Q000209:etiology* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009025:Morpholines / Q000627:therapeutic use*; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects; D011292:Premedication; D015742:Propofol; D013390:Succinylcholine / Q000009:adverse effects; D014508:Urea / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D018686:Anesthetics, Intravenous; D000889:Anti-Arrhythmia Agents; D009025:Morpholines; D009467:Neuromuscular Depolarizing Agents; C077049:landiolol; D014508:Urea; D013390:Succinylcholine; D015742:Propofol